Defence Therapeutics Inc.
DTC
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.02% | 32.65% | 90.60% | 72.84% | 23.44% |
| Total Depreciation and Amortization | -60.85% | -26.35% | 149.02% | 36.84% | 5,816.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 61.25% | 245.88% | -95.63% | 82.80% | 10,000.00% |
| Change in Net Operating Assets | -88.34% | -592.14% | -113.88% | -26.49% | 244.87% |
| Cash from Operations | -53.02% | -99.27% | 53.39% | 106.05% | 75.69% |
| Capital Expenditure | -- | -- | -- | -- | 435.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -187.10% | 100.00% | -- | -- | 435.14% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 57.69% | -188.46% | -1,976.81% | -89.12% | -225.81% |
| Issuance of Common Stock | -100.00% | 190.59% | 88.77% | -- | -99.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -98.56% | 40.72% | -- | 100.00% |
| Cash from Financing | -117.70% | 181.15% | 59.90% | 13.76% | -97.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -82.97% | 1,019.62% | 99.93% | 105.09% | -430.43% |